Combining cognitive therapy and medication for mood disorders

Edward S. Friedman, Jesse H. Wright, Robin B. Jarrett, Michael E. Thase

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Studies of CT in combination with medication, in general, demonstrate a benefit for combination treatment over pharmacotherapy alone in some yet-to-be-identified subgroups of patients with depression. It appears that combination pharmacotherapy plus CT will become the treatment of choice for patients with bipolar illness. Long-range outcomes of patients with major depressive disorder are better when CT is included, regardless of whether CT is concurrent with or follows pharmacotherapy. The research challenge ahead is to determine which patients will most benefit from combined treatment and what is the optimal sequencing of treatments to achieve symptomatic remission, to prevent relapse, to produce recovery, and to avoid recurrence. As in the Keller9 study, reports of moderators of therapeutic response are beginning to be identified and point the way to a more sophisticated model of treatment. As the field identifies these moderators of CT and medication response, our preceding speculations should be replaced with and be continuously updated by more refined, evidence based recommendations, guidelines for, and pathways of treatment.

Original languageEnglish (US)
Pages (from-to)320-328
Number of pages9
JournalPsychiatric Annals
Volume36
Issue number5
StatePublished - May 2006

Fingerprint

Cognitive Therapy
Mood Disorders
Drug Therapy
Therapeutics
Recurrence
Major Depressive Disorder
Guidelines
Depression
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Friedman, E. S., Wright, J. H., Jarrett, R. B., & Thase, M. E. (2006). Combining cognitive therapy and medication for mood disorders. Psychiatric Annals, 36(5), 320-328.

Combining cognitive therapy and medication for mood disorders. / Friedman, Edward S.; Wright, Jesse H.; Jarrett, Robin B.; Thase, Michael E.

In: Psychiatric Annals, Vol. 36, No. 5, 05.2006, p. 320-328.

Research output: Contribution to journalArticle

Friedman, ES, Wright, JH, Jarrett, RB & Thase, ME 2006, 'Combining cognitive therapy and medication for mood disorders', Psychiatric Annals, vol. 36, no. 5, pp. 320-328.
Friedman ES, Wright JH, Jarrett RB, Thase ME. Combining cognitive therapy and medication for mood disorders. Psychiatric Annals. 2006 May;36(5):320-328.
Friedman, Edward S. ; Wright, Jesse H. ; Jarrett, Robin B. ; Thase, Michael E. / Combining cognitive therapy and medication for mood disorders. In: Psychiatric Annals. 2006 ; Vol. 36, No. 5. pp. 320-328.
@article{0652054b0a744608bd9f64ec83f785f1,
title = "Combining cognitive therapy and medication for mood disorders",
abstract = "Studies of CT in combination with medication, in general, demonstrate a benefit for combination treatment over pharmacotherapy alone in some yet-to-be-identified subgroups of patients with depression. It appears that combination pharmacotherapy plus CT will become the treatment of choice for patients with bipolar illness. Long-range outcomes of patients with major depressive disorder are better when CT is included, regardless of whether CT is concurrent with or follows pharmacotherapy. The research challenge ahead is to determine which patients will most benefit from combined treatment and what is the optimal sequencing of treatments to achieve symptomatic remission, to prevent relapse, to produce recovery, and to avoid recurrence. As in the Keller9 study, reports of moderators of therapeutic response are beginning to be identified and point the way to a more sophisticated model of treatment. As the field identifies these moderators of CT and medication response, our preceding speculations should be replaced with and be continuously updated by more refined, evidence based recommendations, guidelines for, and pathways of treatment.",
author = "Friedman, {Edward S.} and Wright, {Jesse H.} and Jarrett, {Robin B.} and Thase, {Michael E.}",
year = "2006",
month = "5",
language = "English (US)",
volume = "36",
pages = "320--328",
journal = "Psychiatric Annals",
issn = "0048-5713",
publisher = "Slack Incorporated",
number = "5",

}

TY - JOUR

T1 - Combining cognitive therapy and medication for mood disorders

AU - Friedman, Edward S.

AU - Wright, Jesse H.

AU - Jarrett, Robin B.

AU - Thase, Michael E.

PY - 2006/5

Y1 - 2006/5

N2 - Studies of CT in combination with medication, in general, demonstrate a benefit for combination treatment over pharmacotherapy alone in some yet-to-be-identified subgroups of patients with depression. It appears that combination pharmacotherapy plus CT will become the treatment of choice for patients with bipolar illness. Long-range outcomes of patients with major depressive disorder are better when CT is included, regardless of whether CT is concurrent with or follows pharmacotherapy. The research challenge ahead is to determine which patients will most benefit from combined treatment and what is the optimal sequencing of treatments to achieve symptomatic remission, to prevent relapse, to produce recovery, and to avoid recurrence. As in the Keller9 study, reports of moderators of therapeutic response are beginning to be identified and point the way to a more sophisticated model of treatment. As the field identifies these moderators of CT and medication response, our preceding speculations should be replaced with and be continuously updated by more refined, evidence based recommendations, guidelines for, and pathways of treatment.

AB - Studies of CT in combination with medication, in general, demonstrate a benefit for combination treatment over pharmacotherapy alone in some yet-to-be-identified subgroups of patients with depression. It appears that combination pharmacotherapy plus CT will become the treatment of choice for patients with bipolar illness. Long-range outcomes of patients with major depressive disorder are better when CT is included, regardless of whether CT is concurrent with or follows pharmacotherapy. The research challenge ahead is to determine which patients will most benefit from combined treatment and what is the optimal sequencing of treatments to achieve symptomatic remission, to prevent relapse, to produce recovery, and to avoid recurrence. As in the Keller9 study, reports of moderators of therapeutic response are beginning to be identified and point the way to a more sophisticated model of treatment. As the field identifies these moderators of CT and medication response, our preceding speculations should be replaced with and be continuously updated by more refined, evidence based recommendations, guidelines for, and pathways of treatment.

UR - http://www.scopus.com/inward/record.url?scp=33745164938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745164938&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33745164938

VL - 36

SP - 320

EP - 328

JO - Psychiatric Annals

JF - Psychiatric Annals

SN - 0048-5713

IS - 5

ER -